Brodstein R S, Brodstein D E, Olson R J, Hunt S C, Williams R R
Ophthalmology. 1984 Nov;91(11):1373-9. doi: 10.1016/s0161-6420(84)34138-0.
Two hundred fifty-three patients were followed for up to nine years (mean, 4 1/4 years). They were on a regimen of atropine 1% once a day in an attempt to retard myopic progression. Their rate of myopic progression prior to atropine treatment was compared with 146 controls. The rates of myopic progression during and after treatment were also compared to those of the controls. The results from several analyses showed a marked flattening in the rate of myopic progression during treatment, and the rate of myopic progression after treatment ran parallel to those in the control group. Age in relation to myopic progression was evaluated in subgroups. A variation existed in the rate of myopic progression in the controls. The fastest rate of myopic progression occurred between eight and 12 years of age, and the slowest rate of myopic progression developed in those patients over 18 years of age.
253名患者被随访长达9年(平均4.25年)。他们接受了每天一次1%阿托品的治疗方案,试图延缓近视进展。将他们在阿托品治疗前的近视进展速度与146名对照组进行了比较。还将治疗期间和治疗后的近视进展速度与对照组进行了比较。多项分析结果显示,治疗期间近视进展速度明显变缓,治疗后的近视进展速度与对照组平行。在亚组中评估了年龄与近视进展的关系。对照组的近视进展速度存在差异。近视进展最快的速度出现在8至12岁之间,而进展最慢的速度出现在18岁以上的患者中。